INS and metabolic syndrome: Previous studies have demonstrated that higher serum IGFBP-rp1 is involved in the early defect of insulin actions; therefore, it serves as a marker of insulin resistance, metabolic syndrome, T2DM, and related cardiovascular complications [41].